Who
Jill M. Quigley
Director
Company insider
Files Form 4 as: Sr. Advisor & Strategy Officer, Terns Pharmaceuticals; Director, Chemomab Therapeutics; Chief Operating Officer, Passage Bio.
In numbers
- Trades disclosed
- 51
- Buys
- 1
- Sells
- 10
- Bought
- $45K
- Sold
- $1.5M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 27 Feb 2020
- Last trade
- 5 May 2026
- Last filed
- 5 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —45,000 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,657 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —32,000 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —45,000 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —10,657 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —32,000 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —3,955 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —22,000 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —32,000 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —1,697 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —3,955 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —22,000 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —32,000 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,697 | filing |
| 1 Feb 2026filed 2 Feb 2026 | Terns Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,697 at $0.00 | filing |
| 1 Feb 2026filed 2 Feb 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —1,697 at $0.00 | filing |
| 4 Nov 2025filed 5 Nov 2025 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code M | —24,520 at $0.00 | filing |
| 4 Nov 2025filed 5 Nov 2025 | Terns Pharmaceuticals | SEC FORM 4 Code M | $227K24,520 at $9.24 | filing |
| 4 Nov 2025filed 5 Nov 2025 | Terns Pharmaceuticals | SEC FORM 4 Sold | $441K24,520 at $18.00 | filing |
| 11 Jun 2025filed 12 Jun 2025 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.